Ticker Details
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date:	October 23, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$968.6M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.45 | 3.18%
Avg Daily Range (30 D):	$0.09 | 3.84%
Avg Daily Range (90 D):	$0.08 | 3.51%

Institutional Daily Volume
Avg Daily Volume:	3.84M
Avg Daily Volume (30 D):	10.62M
Avg Daily Volume (90 D):	12.09M

Trade Size
Avg Trade Size (Sh.):	178
Avg Trade Size (Sh.) (30 D):	425
Avg Trade Size (Sh.) (90 D):	422

Institutional Trades
Total Institutional Trades:	5,394
Avg Institutional Trade:	$2.54M
Avg Institutional Trade (30 D):	$2.42M
Avg Institutional Trade (90 D):	$1.86M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.9M
Avg Closing Trade (30 D):	$2.61M
Avg Closing Trade (90 D):	$1.78M
Avg Closing Volume:	382.06K

News

Dec 19, 2025 @ 10:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

Dec 7, 2025 @ 2:25 PM 2 Stocks That Could Soar by 52% and 282%, Accordin... Source: Prosper Junior Bakiny

Oct 17, 2025 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Iovance Biotherapeutics, Inc.

Oct 17, 2025 @ 10:17 AM Better Beaten-Down Stock: Iovance Biotherapeutics ... Source: Prosper Junior Bakiny

Sep 17, 2025 @ 12:30 PM Advancing Cancer Research Brings New Hope for Pati... Source: Prnewswire

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-.25	$-.33	$-.36
Diluted EPS		$-.33	$-.36
Revenue	$67.46M	$59.95M	$49.32M
Gross Profit	$28.98M	$3.29M	$-.42M
Net Income / Loss	$-91.25M	$-111.66M	$-116.16M
Operating Income / Loss	$-94.9M	$-113.77M	$-121.22M
Cost of Revenue	$38.48M	$56.66M	$49.74M
Net Cash Flow	$25.69M	$-39.64M	$56M
PE Ratio

Splits
Sep 26, 2013	1:100
Apr 06, 2010	24:1